NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,196.43 mln
Float21.31 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
0.8
Highly suspicious
1-Year Forecast
153
Transformational upside
Relative Strength
8
/ 100
Severely lagging
Debt / Equity
0.14
Very low leverage
ROE
-107
Deeply negative
Business Description
Nektar Therapeutics is a San Francisco-based biopharmaceutical company founded in 1990 that researches and develops treatments for autoimmune, inflammatory, fibrotic, and oncological conditions. Its pipeline includes several compounds at various stages of clinical development, targeting diseases such as ulcerative colitis, multiple sclerosis, and certain cancers. The company works alongside a number of major pharmaceutical partners, including Pfizer, AstraZeneca, Bristol-Myers Squibb, and Merck, among others.
